Narcolepsy – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Narcolepsy – Pipeline Review, H1 2017’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Narcolepsy

The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects

The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Narcolepsy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Narcolepsy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

Reset Therapeutics Inc

Sanofi

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Theranexus SAS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Narcolepsy - Overview

Narcolepsy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Narcolepsy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Narcolepsy - Companies Involved in Therapeutics Development

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

Reset Therapeutics Inc

Sanofi

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Theranexus SAS

Narcolepsy - Drug Profiles

(flecainide acetate + modafinil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-386 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JZP-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LGD-3437 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-110068 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-N05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium oxybate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-091 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Narcolepsy - Dormant Projects

Narcolepsy - Discontinued Products

Narcolepsy - Product Development Milestones

Featured News & Press Releases

Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Apr 24, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy

Mar 15, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Feb 13, 2017: Lincoln Medical's Wakix Rejects For Use Within NHS Scotland

Jan 25, 2017: A New Study Published by The Lancet Neurology Shows Efficacy of Pitolisant (Wakix) on Cataplexy in Patients with Narcolepsy

Dec 16, 2016: Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy

Nov 28, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy

Oct 27, 2016: Inclusion of the First Patient in the Phase II Clinical Study That Aims to Test THN102 in Patients Affected by Narcolepsy

Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218

Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy

Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US & Europe for Treatment of Narcolepsy

Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting

May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness

Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate

Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Narcolepsy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Narcolepsy – Pipeline by Avadel Pharmaceuticals Plc, H1 2017

Narcolepsy – Pipeline by Bioprojet SCR, H1 2017

Narcolepsy – Pipeline by Evotec AG, H1 2017

Narcolepsy – Pipeline by H.A.C. Pharma, H1 2017

Narcolepsy – Pipeline by Heptares Therapeutics Ltd, H1 2017

Narcolepsy – Pipeline by Jazz Pharmaceuticals Plc, H1 2017

Narcolepsy – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Narcolepsy – Pipeline by OptiNose US Inc, H1 2017

Narcolepsy – Pipeline by Reset Therapeutics Inc, H1 2017

Narcolepsy – Pipeline by Sanofi, H1 2017

Narcolepsy – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Narcolepsy – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017

Narcolepsy – Pipeline by Theranexus SAS, H1 2017

Narcolepsy – Dormant Projects, H1 2017

Narcolepsy – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Narcolepsy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports